PTC Therapeutics, Inc. Finance Lease, Liability
PTC Therapeutics, Inc. (PTCT) had Finance Lease, Liability of $6.00 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Balance Sheet › Liabilities
us-gaap:FinanceLeaseLiability · last filed 2026-02-19
- 2025-12-31: Finance Lease, Liability $6.00M.
- 2025-09-30: Finance Lease, Liability $16.51M.
- 2025-06-30: Finance Lease, Liability $19.19M.
- 2025-03-31: Finance Lease, Liability $18.88M.
| Period end | Finance Lease, Liability |
|---|---|
| 2025-12-31 | $6.00M 10-K · filed 2026-02-19 |
| 2025-09-30 | $16.51M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $19.19M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $18.88M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $18.57M 10-K · filed 2025-02-27 |
| 2024-09-30 | $18.22M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $17.87M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $17.52M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $20.18M 10-K · filed 2024-02-29 |
| 2023-09-30 | $19.80M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $19.41M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $19.04M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $21.68M 10-K · filed 2023-02-21 |
| 2022-09-30 | $21.26M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $20.05M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $20.45M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $23.05M 10-K · filed 2022-02-22 |
| 2021-09-30 | $22.61M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $22.17M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $21.75M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $24.33M 10-Q · filed 2021-10-28 |
| 2020-09-30 | $23.86M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $26.21M 10-Q · filed 2020-08-05 |
| 2019-12-31 | $0.00 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |